What is the average resistance period to lapatinib/telisate?

The problem of resistance to Lapatinib is a long-term core issue in the field of HER2-targeted therapy. Generally speaking, after patients receive lapatinib treatment, the average resistance period is concentrated between 9 and 14 months, but this time is not fixed and depends on the patient's tumor type, genetic characteristics, previous medication history, and whether it is combined with other drugs and other factors. The essential cause of drug resistance lies in the adaptive mutation of genes in tumor cells and the bypass activation of signaling pathways, which causes the drug to lose its original inhibitory effect.

Lapatinib blocks cell proliferation signals by inhibiting the HER2 and EGFR pathways, but tumor cells may evade the drug's effects through a variety of mechanisms under long-term exposure. For example, the PI3K/AKT or MAPK signaling pathway downstream of the HER2 receptor is reactivated, or other receptors such as HER3 and MET participate in compensatory signaling, causing cells to continue to proliferate. In addition, some patients may have HER2 gene mutations or copy number changes, which may change the drug binding site, thereby reducing the binding efficiency of lapatinib.

In order to prolong the curative effect, clinical combination strategies are often used, such as combining with capecitabine or trastuzumab to block signaling pathways at different levels, thereby delaying the occurrence of drug resistance. In recent years, researchers have also found that changes in the immune microenvironment can also affect the process of drug resistance. For example, tumor-associated macrophages and cytokine secretion can indirectly promote the formation of drug resistance.

In overseas studies, some patients can significantly extend their progression-free survival through drug alternation or sequential treatment. For example, switching to new HER2 inhibitors such as neratinib or tucatinib can regain efficacy after resistance occurs. In the future, with the popularization of molecular detection technology, doctors will be able to identify drug resistance signals earlier and make precise adjustments to extend the use period of lapatinib on an individualized basis.

Reference materials:https://medlineplus.gov/druginfo/meds/a607055.html